Transplant factors based on multivariate analyses
| Parameter . | N . | HR (95% CI) . | P . |
|---|---|---|---|
| GF and/or second HCT | |||
| Conditioning intensity | .228∗ | ||
| Bu/Cy | 62 | 1.0 | |
| Alternative regimens | 177 | 1.60 (0.74-3.45) | .228 |
| Conditioning regimen | .029∗ | ||
| Busulfan-based | 192 | 1.0 | |
| Melphalan-based | 29 | 2.52 (1.23-5.18) | .012 |
| Other | 18 | 1.87 (0.74-4.72) | .187 |
| Grade 2-4 aGVHD | |||
| Serotherapy† | .004∗ | ||
| None | 20 | 1.0 | |
| ATG | 103 | 0.44 (0.17-1.11) | .083 |
| Alemtuzumab | 110 | 0.20 (0.07-0.54) | .002 |
| Donor type | .012∗ | ||
| MRD | 56 | 1.0 | |
| MMRD | 21 | 4.36 (1.18-16.1) | .027 |
| MUD | 117 | 5.27 (1.76-15.75) | .003 |
| MMUD | 39 | 6.87 (2.13-22.19) | .001 |
| Chronic GVHD | |||
| Inflammatory disease‡ | .037∗ | ||
| No | 132 | 1.0 | |
| Yes | 87 | 2.17 (1.06-4.43) | .037 |
| Pulmonary infection‡ | .006∗ | ||
| No | 139 | 1.0 | |
| Yes | 80 | 2.68 (1.33-5.42) | .006 |
| OS | |||
| Performance status | .004∗ | ||
| Lansky/Karnofsky ≥90 | 193 | 1.0 | |
| Lansky/Karnofsky <90 | 25 | .001 | |
| Unknown | 21 | 3.50 (1.63-7.50) | .735 |
| Donor HLA match | .012∗ | ||
| Matched (MRD + MUD) | 178 | 1.0 | |
| Mismatched (MMRD + MMUD) | 61 | 2.26 (1.19-4.28) | .012 |
| EFS§ | |||
| Performance status | <.001∗ | ||
| Lansky/Karnofsky ≥90 | 193 | 1.0 | |
| Lansky/Karnofsky <90 | 25 | 3.01 (1.66-5.46) | <.001 |
| Unknown | 21 | .636 | |
| Donor HLA match | .019∗ | ||
| Matched (MRD + MUD) | 178 | 1.0 | |
| Mismatched (MMRD + MMUD) | 61 | 1.81 (1.10-2.96) | .019 |
| Parameter . | N . | HR (95% CI) . | P . |
|---|---|---|---|
| GF and/or second HCT | |||
| Conditioning intensity | .228∗ | ||
| Bu/Cy | 62 | 1.0 | |
| Alternative regimens | 177 | 1.60 (0.74-3.45) | .228 |
| Conditioning regimen | .029∗ | ||
| Busulfan-based | 192 | 1.0 | |
| Melphalan-based | 29 | 2.52 (1.23-5.18) | .012 |
| Other | 18 | 1.87 (0.74-4.72) | .187 |
| Grade 2-4 aGVHD | |||
| Serotherapy† | .004∗ | ||
| None | 20 | 1.0 | |
| ATG | 103 | 0.44 (0.17-1.11) | .083 |
| Alemtuzumab | 110 | 0.20 (0.07-0.54) | .002 |
| Donor type | .012∗ | ||
| MRD | 56 | 1.0 | |
| MMRD | 21 | 4.36 (1.18-16.1) | .027 |
| MUD | 117 | 5.27 (1.76-15.75) | .003 |
| MMUD | 39 | 6.87 (2.13-22.19) | .001 |
| Chronic GVHD | |||
| Inflammatory disease‡ | .037∗ | ||
| No | 132 | 1.0 | |
| Yes | 87 | 2.17 (1.06-4.43) | .037 |
| Pulmonary infection‡ | .006∗ | ||
| No | 139 | 1.0 | |
| Yes | 80 | 2.68 (1.33-5.42) | .006 |
| OS | |||
| Performance status | .004∗ | ||
| Lansky/Karnofsky ≥90 | 193 | 1.0 | |
| Lansky/Karnofsky <90 | 25 | .001 | |
| Unknown | 21 | 3.50 (1.63-7.50) | .735 |
| Donor HLA match | .012∗ | ||
| Matched (MRD + MUD) | 178 | 1.0 | |
| Mismatched (MMRD + MMUD) | 61 | 2.26 (1.19-4.28) | .012 |
| EFS§ | |||
| Performance status | <.001∗ | ||
| Lansky/Karnofsky ≥90 | 193 | 1.0 | |
| Lansky/Karnofsky <90 | 25 | 3.01 (1.66-5.46) | <.001 |
| Unknown | 21 | .636 | |
| Donor HLA match | .019∗ | ||
| Matched (MRD + MUD) | 178 | 1.0 | |
| Mismatched (MMRD + MMUD) | 61 | 1.81 (1.10-2.96) | .019 |
Cy, cyclophosphamide.
Denotes overall P value, comparing all groups for that variable.
Pairwise comparison of ATG only vs alemtuzumab only: HR for Grade 2-4 aGVHD of 0.46 (0.23-0.91); P = .025. There was no effect on GF (P = .691).
History of inflammatory disease or pulmonary infection in the year prior to HCT regardless of control/resolution status
Events include GF, need for subsequent transplant, and death